This article was originally published in The Rose Sheet
Executive SummaryPatients who suffer from allergic contact dermatitis due to treatment with topical minoxidil solution "should be advised to undergo patch testing to determine the causative allergen," researchers report in the February Journal of the American Academy of Dermatology. Edward Friedman, et al., New York University School of Medicine, suggest these patients could be sensitive to an agent in the solution other than minoxidil, such as propylene glycol, in which case "they should be given the option of formulations compounded with alternative solvents." Friedman et al. patch tested 11 individuals with alopecia; nine showed a positive allergic reaction to propylene glycol, while only four reacted to minoxidil...
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.